212 related articles for article (PubMed ID: 14563790)
1. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine.
Richter T; Mürdter TE; Heinkele G; Pleiss J; Tatzel S; Schwab M; Eichelbaum M; Zanger UM
J Pharmacol Exp Ther; 2004 Jan; 308(1):189-97. PubMed ID: 14563790
[TBL] [Abstract][Full Text] [Related]
2. Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel.
Nishiya Y; Hagihara K; Ito T; Tajima M; Miura S; Kurihara A; Farid NA; Ikeda T
Drug Metab Dispos; 2009 Mar; 37(3):589-93. PubMed ID: 19047469
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.
Turpeinen M; Nieminen R; Juntunen T; Taavitsainen P; Raunio H; Pelkonen O
Drug Metab Dispos; 2004 Jun; 32(6):626-31. PubMed ID: 15155554
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-based.
Richter T; Schwab M; Eichelbaum M; Zanger UM
Biochem Pharmacol; 2005 Feb; 69(3):517-24. PubMed ID: 15652242
[TBL] [Abstract][Full Text] [Related]
5. A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1',1''-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6.
Walsky RL; Obach RS
Drug Metab Dispos; 2007 Nov; 35(11):2053-9. PubMed ID: 17682072
[TBL] [Abstract][Full Text] [Related]
6. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
Kazui M; Nishiya Y; Ishizuka T; Hagihara K; Farid NA; Okazaki O; Ikeda T; Kurihara A
Drug Metab Dispos; 2010 Jan; 38(1):92-9. PubMed ID: 19812348
[TBL] [Abstract][Full Text] [Related]
7. Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel.
Nishiya Y; Hagihara K; Kurihara A; Okudaira N; Farid NA; Okazaki O; Ikeda T
Xenobiotica; 2009 Nov; 39(11):836-43. PubMed ID: 19845434
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes.
Bae SK; Cao S; Seo KA; Kim H; Kim MJ; Shon JH; Liu KH; Zhou HH; Shin JG
Drug Metab Dispos; 2008 Aug; 36(8):1679-88. PubMed ID: 18474675
[TBL] [Abstract][Full Text] [Related]
9. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine.
Hagihara K; Nishiya Y; Kurihara A; Kazui M; Farid NA; Ikeda T
Drug Metab Pharmacokinet; 2008; 23(6):412-20. PubMed ID: 19122335
[TBL] [Abstract][Full Text] [Related]
10. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols.
Lau AJ; Chang TK
Drug Metab Dispos; 2009 Sep; 37(9):1931-7. PubMed ID: 19487249
[TBL] [Abstract][Full Text] [Related]
12. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.
Turpeinen M; Tolonen A; Uusitalo J; Jalonen J; Pelkonen O; Laine K
Clin Pharmacol Ther; 2005 Jun; 77(6):553-9. PubMed ID: 15961986
[TBL] [Abstract][Full Text] [Related]
13. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
Xu C; Ogburn ET; Guo Y; Desta Z
Drug Metab Dispos; 2012 Apr; 40(4):717-25. PubMed ID: 22232427
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of endosulfan-alpha by human liver microsomes and its utility as a simultaneous in vitro probe for CYP2B6 and CYP3A4.
Casabar RC; Wallace AD; Hodgson E; Rose RL
Drug Metab Dispos; 2006 Oct; 34(10):1779-85. PubMed ID: 16855053
[TBL] [Abstract][Full Text] [Related]
15. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
Hesse LM; von Moltke LL; Shader RI; Greenblatt DJ
Drug Metab Dispos; 2001 Feb; 29(2):100-2. PubMed ID: 11159797
[TBL] [Abstract][Full Text] [Related]
16. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.
Faucette SR; Hawke RL; Lecluyse EL; Shord SS; Yan B; Laethem RM; Lindley CM
Drug Metab Dispos; 2000 Oct; 28(10):1222-30. PubMed ID: 10997944
[TBL] [Abstract][Full Text] [Related]
17. Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro.
Chang SY; Chen C; Yang Z; Rodrigues AD
Drug Metab Dispos; 2009 Aug; 37(8):1667-75. PubMed ID: 19454483
[TBL] [Abstract][Full Text] [Related]
18. The development of a cocktail CYP2B6, CYP2C8, and CYP3A5 inhibition assay and a preliminary assessment of utility in a drug discovery setting.
O'Donnell CJ; Grime K; Courtney P; Slee D; Riley RJ
Drug Metab Dispos; 2007 Mar; 35(3):381-5. PubMed ID: 17142561
[TBL] [Abstract][Full Text] [Related]
19. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin.
Clarke TA; Waskell LA
Drug Metab Dispos; 2003 Jan; 31(1):53-9. PubMed ID: 12485953
[TBL] [Abstract][Full Text] [Related]
20. Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4.
Ohbuchi M; Noguchi K; Kawamura A; Usui T
Xenobiotica; 2012 Jul; 42(7):633-40. PubMed ID: 22313038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]